SecBot SecBot
Biotech Drug Report Generated Sep 5, 2026

FHD-909

FHTX·Foghorn Therapeutics Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 1
Time to market
Unknown, the drug is in early Phase 1 dose-escalation. Assuming successful development, a potential approval would be several years away (likely 2029+).
Why 4/10
FHD-909 is in Phase 1 dose-escalation with no specific dated binary catalyst (PDUFA, pivotal readout, or announced data-readout date) scheduled in the next ~12 months. The next hard catalyst would be Phase 1 clinical data, but no date has been set. Per the rubric, a Phase 1 drug without a dated binary within 12 months scores 4.
Actionable Insight NEUTRAL

Monitor for any announced Phase 1 data readout date or interim results from the FHD-909 dose-escalation trial, which would be the next major catalyst. Also watch the December 2026 Lilly collaboration term expiration for potential restructuring or milestone news. The stock's ~144% implied upside to analyst targets reflects optimism about the platform, but early-stage clinical risk remains substantial.

Price Chart

Loading chart...

Executive Summary

FHD-909 (LY4050784) is a selective SMARCA2 inhibitor in Phase 1 dose-escalation for SMARCA4-mutant cancers, primarily NSCLC, developed by Foghorn Therapeutics (Nasdaq: FHTX) in partnership with Eli Lilly. Preclinical data at AACR 2026 showed promising complete tumor regression in combination with anti-PD-1. The stock trades at ~$4.92 with a strong-buy analyst consensus and a mean $11.44 price target. However, the drug is early-stage with no human efficacy data yet, the Lilly collaboration term expires in December 2026, and another pipeline program (CBPd-171) recently hit a delay, making FHD-909 a high-risk/high-potential asset without a near-term binary catalyst.

How It Works

FHD-909 is a selective SMARCA2 inhibitor, an oral targeted cancer therapy. It exploits a genetic vulnerability: certain cancers (especially non-small cell lung cancer) lose the SMARCA4 gene and become dependent on its close cousin SMARCA2 to survive. By blocking SMARCA2, FHD-909 selectively kills SMARCA4-mutant cancer cells while sparing normal cells. Preclinical data also suggest it works well with immunotherapy (anti-PD-1).

Trial Status

FHD-909 is in a Phase 1 dose-escalation trial targeting SMARCA4 (BRG1)-mutant cancers, primarily non-small cell lung cancer (NSCLC). The trial was reported as "on track" and "advancing as planned" in Foghorn's Q2 2026 earnings update (August 2026). Preclinical data presented at AACR 2026 showed complete and durable tumor regression in combination with anti-PD-1 in mouse models, along with anti-tumor immune memory.

The Two-Sided Case

▲ Bull Case4
Preclinical data at AACR 2026 showed complete and durable tumor regression with FHD-909 + anti-PD-1 combination, plus anti-tumor immune memory, a strong signal for a differentiated mechanism in SMARCA4-mutant NSCLC.
Analyst consensus is Strong Buy (15 Buy/Strong Buy vs 1 Hold) with a mean price target of $11.44, implying ~144% upside from the current ~$4.92 price.
FHD-909 is partnered with Eli Lilly (code LY4050784), providing validation and potential milestone/revenue support; Foghorn had $167.6M cash as of Q2 2026 with runway into H1 2028.
Large institutional holders include FMR LLC ($27.8M), BlackRock ($12.8M), and Raymond James ($12.2M) as of Q2 2026.
▼ Bear Case5
FHD-909 is in early Phase 1 dose-escalation, no human efficacy data yet; preclinical results often fail to translate to patients.
The Lilly collaboration research term expires in December 2026, creating a potential revenue cliff and uncertainty about future partnership terms.
Foghorn's CBPd-171 (FHT-171) program was delayed due to a CRO operational issue, raising concerns about broader execution risk.
As a pre-revenue biotech with no approved products, FHTX stock is highly sensitive to pipeline setbacks and may face dilution risk despite current cash runway into H1 2028.
Short-volume ratio has periodically spiked above 55% (elevated signal), indicating active short interest in the stock.

Upcoming Catalysts

  • Phase 1 dose-escalation data readout (no specific date announced yet)
  • Lilly collaboration research term expiration (December 2026), could trigger partnership restructuring or milestone payments
  • Potential clinical data updates at future medical conferences

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Foghorn Therapeutics Inc. 8-K FHTX ·Originating report

Sources · 6

Hover a chip for the title
1 sec.gov2 globenewswire.com3 globenewswire.com4 globenewswire.com5 globenewswire.com6 globenewswire.com